Reimbursement Review Reports

The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.

Brand Name Generic Name Therapeutic Area Recommendation Type Project Status Date Submission Received Date Recommendation Issued Sort descending
Revolade eltrombopag CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Symdeko tezacaftor/ivacaftor CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
TBC etonogestrel Prevention of pregnancy Withdrawn
Tecentriq Atezolizumab Withdrawn
Orilissa elagolix CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Keytruda Pembrolizumab CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Lynparza Olaparib CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
TBC filgotinib Arthritis, Rheumatoid Withdrawn
Firazyr icatibant CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed
Oncaspar Pegaspargase CADTH is unable to recommend reimbursement as a submission was not filed by the manufacturer Not filed